Skip to search formSkip to main contentSkip to account menu

AZD1775

Known as: AZD-1775, WEE1 Inhibitor AZD1775 
A small molecule inhibitor of the tyrosine kinase WEE1 with potential antineoplastic sensitizing activity. AZD1775 selectively targets and inhibits… 
National Institutes of Health

Related topics

Related topics

3 relations
MK 1775NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Wee1 Inhibitor AZD1775 Effectively Inhibits the Malignant Phenotypes of Esophageal Squamous Cell Carcinoma In Vitro and In Vivo
Esophageal squamous cell carcinoma (ESCC) is a common malignant diagnosed cancer with increasing incidence rate and few treatment… 
2019
2019
Abstract CT138: NCI-MATCH EAY131 -Z1I: Phase II study of AZD1775, a wee-1 kinase inhibitor, in patients with tumors containingBRCA1andBRCA2mutations
Background: Wee1 is a tyrosine kinase implicated in the inhibitory phosphorylation of CDK1/CDC2-bound cyclin B complex… 
2018
2018
VIOLETTE: A randomized phase II study to assess DNA damage response inhibitors in combination with olaparib (Ola) vs Ola monotherapy in patients (pts) with metastatic, triple-negative breast cancer…
TPS1116Background: Invasive BC is diagnosed in > 255,000 pts in the US annually, and TNBC comprises ≈15% of cases. Alterations in… 
2017
2017
Replication Stress Leading to Apoptosis within the S-phase Contributes to Synergism between Vorinostat and AZD1775 in HNSCC Harboring High-Risk TP53 Mutation
Purpose: The cure rate for patients with advanced head and neck squamous cell carcinoma (HNSCC) remains poor due to resistance to… 
2017
2017
Abstract CT144: Pediatric phase I trial of the WEE1 inhibitor AZD1775 and irinotecan in patients with refractory solid and CNS malignancies; A Children’s Oncology Group Study (ADVL1312)
Background: Inhibition of the WEE1 kinase by AZD1775 potentiates replicative stress induced by oncogenes or chemotherapy, and… 
2016
2016
A phase Ib study of AZD1775 and olaparib combination in patients with refractory solid tumors.
5562Background: Tumors with G1/S checkpoint deficiencies rely on Wee1 kinase to arrest cell cycle progression at G2/M to repair… 
2016
2016
Phase ib trial of dose-escalating AZD1775 in combination with concurrent radiation and cisplatin for intermediate and high risk head and neck squamous cell carcinoma.
TPS6106Background: Patients with significant tobacco histories (intermediate risk) and those who are HPV negative (high risk… 
2016
2016
Abstract CT013: A phase Ib, open-label, multicenter study to assess the safety, tolerability, pharmacokinetics, and antitumor activity of AZD1775 monotherapy in patients with advanced solid tumors…
Many cancers are associated with DNA repair and cell cycle mutations that result in G1/S checkpoint deficiencies and higher… 
2015
2015
An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.
5506 Background: Data suggest synthetic lethality when TP53-deficient cells are exposed to genotoxic drugs plus the Wee1… 
2014
2014
Phase I trial of AZD1775 (MK1775), a wee1 kinase inhibitor, in patients with refractory solid tumors.
2503 Background: Wee1 tyrosine kinase phosphorylates and inactivates Cdk1, causing G2 cell cycle arrest in response to DNA damage… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)